These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
105 related items for PubMed ID: 17645715
1. Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamune and microemulsion cyclosporine protocol. Pelletier RP, Soule J, Henry ML, Rajab A, Ferguson RM. Clin Transplant; 2007; 21(4):532-5. PubMed ID: 17645715 [Abstract] [Full Text] [Related]
8. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S. Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352 [Abstract] [Full Text] [Related]
9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW. Clin Transplant; 1997 Aug 20; 11(4):299-312. PubMed ID: 9267719 [Abstract] [Full Text] [Related]
10. Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation. Segovia J, Gerosa G, Almenar L, Livi U, Viganò M, Arizón JM, Yonan N, Di Salvo TG, Renlund DG, Kobashigawa JA, ERL 2401 Study Group. Clin Transplant; 2008 Aug 20; 22(6):809-14. PubMed ID: 18702660 [Abstract] [Full Text] [Related]
11. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. Kobashigawa JA, Renlund DG, Gerosa G, Almenar L, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U, Ross H, Segovia J, Yonan N, ERL2401 Heart Study Investigators. J Heart Lung Transplant; 2006 Aug 20; 25(8):935-41. PubMed ID: 16890114 [Abstract] [Full Text] [Related]
14. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data. Trkulja V, Lalić Z, Nađ-Škegro S, Lebo A, Granić P, Lovrić M, Pasini J, Božina N. Ther Drug Monit; 2014 Aug 20; 36(4):456-64. PubMed ID: 24518562 [Abstract] [Full Text] [Related]
19. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Abramowicz D, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, Gafner N, Wijngaard P, Cyclosporine Withdrawal Study Group. J Am Soc Nephrol; 2005 Jul 20; 16(7):2234-40. PubMed ID: 15917338 [Abstract] [Full Text] [Related]